Pelthos Therapeutics Unveils 2025 Financials, Charting Course for Future Innovations

Five Crucial Stocks to Watch as We Kick Off the Trading Week

Engene Holdings: Why 2026 Could Be Their Pivotal Moment

A Glimmer of Hope for Kidney Disease: Vertex's Breakthrough in IgA Nephropathy

A New Dawn in Pain Relief: Vertex Pharmaceuticals' Breakthrough Soars Stock

Olema Pharmaceuticals Stock Takes a Dive: What Sparked the Sudden Plunge?

The FDA's Quiet Retreat: Fewer Public Debates Amid Rising Controversy

The Uncharted Alliance: Klotho Neurosciences Forges Unexpected Path with Greenland Mining Giant

The Shifting Sands of Pharma: FDA's Grip, Global Ambitions, and the Future of Medicine

A Major Setback: FDA Halts uniQure's Huntington's Gene Therapy Trial

The End of an Era: Doug Ingram Prepares to Retire from Sarepta, Elizabeth Barrett Named Successor

GSK's Bold Move: A $1.8 Billion Bet on the Future of Pulmonary Hypertension Treatment

The Grand Ambition of Early Cancer Detection: Unpacking Tests Like Galleri

A Glimmer of Hope for Crohn's Patients: Stoked Bio's Latest Leap Forward

A Game-Changer on the Horizon: Disc Medicine's Bitopertin and the FDA's Looming Decision

Viking Therapeutics Rockets Skyward: Is Their Obesity Drug the Next Market Game-Changer?

A Regulatory Stumble: FDA Puts Brakes on Moderna's Flu Vaccine Hopes

A Bumpy Road Ahead? FDA Hits Pause on Moderna's Flu Shot Application

The Market's Two Minds: Lilly's High-Stakes Game Meets Housing's Quiet Comeback

Moderna's Big Turnaround: Why Jim Cramer is Eyeing 2026 for Revenue Growth

AstraZeneca's Bold Bet: Charging Hard into China's Obesity Drug Race and Beyond

The AI Wave: Is it Time for 'Monkey Business' to Evolve in Pharma Research?

The J.P. Morgan Healthcare Conference 2026: Day 2 Unpacked

Unlocking New Frontiers: How Revolution Medicines and Merck Are Redefining the Cancer Fight

Alnylam's Ambitious Five-Year Vision: Betting Big on Amvuttra and Beyond

Pune's Biotech Boom: How Startups Are Reshaping Pharma and Life Sciences

Friday's Market Pulse: The Club's Essential Watchlist for the Trading Day

Biohaven's Balancing Act: Cash Cushion Grows, But So Does the Dilution Shadow

Unpacking the Ambition: Trump's Most-Favored-Nation Drug Pricing Push

A Game-Changer for Assembly Bio: Gilead's Nod Sends Stock Soaring

Cytokinetics' Myqorzo Secures Landmark FDA Approval, Reshaping HCM Treatment Landscape

Incyte Unveils Game-Changing Myelofibrosis Data at ASH 2025

ASH 2025: Glimmers of Hope and Big Strides in Blood Disorders

A Glimmer of Hope: Syndax's Novel AML Drug Shines Bright at ASH Meeting

A New Dawn in Cancer Detection: Freenome's Bold Move Towards Public Markets

Vinay Prasad Sounds the Alarm: Media Missteps and Harvard’s Choices Are Hurting Biotech

A New Beacon of Hope: Bristol Myers Squibb's Breyanzi Achieves Fifth FDA Approval

Sensei Biotherapeutics Shares Skyrocket: The Science Behind the Stock Surge

The Anticipation Builds: ASH 2025 and the Evolving Landscape of Blood Cancer Therapies